Trial Profile
Two-part study of elective ionotropic glutamate receptor 5 (iGluR5) antagonist LY545694 studying safety, tolerability, pharmacokinetics, and effects on human experimental pain in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 04 Nov 2015
Price :
$35
*
At a glance
- Drugs LY 545694 (Primary)
- Indications Musculoskeletal pain; Neuropathic pain
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 04 Nov 2015 New trial record